ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria
Open Access
- 1 September 2015
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (9), 5555-5560
- https://doi.org/10.1128/aac.01183-15
Abstract
ELQ-300 is a preclinical candidate that targets the liver and blood stages of Plasmodium falciparum , as well as the forms that are crucial to transmission of disease: gametocytes, zygotes, and ookinetes. A significant obstacle to the clinical development of ELQ-300 is related to its physicochemical properties. Its relatively poor aqueous solubility and high crystallinity limit absorption to the degree that only low blood concentrations can be achieved following oral dosing. While these low blood concentrations are sufficient for therapy, the levels are too low to establish an acceptable safety margin required by regulatory agencies for clinical development. One way to address the challenging physicochemical properties of ELQ-300 is through the development of prodrugs. Here, we profile ELQ-337, a bioreversible O-linked carbonate ester prodrug of the parent molecule. At the molar equivalent dose of 3 mg/kg of body weight, the delivery of ELQ-300 from ELQ-337 is enhanced by 3- to 4-fold, reaching a maximum concentration of drug in serum ( C max ) of 5.9 μM by 6 h after oral administration, and unlike ELQ-300 at any dose, ELQ-337 provides single-dose cures of patent malaria infections in mice at low-single-digit milligram per kilogram doses. Our findings show that the prodrug strategy represents a viable approach to overcome the physicochemical limitations of ELQ-300 to deliver the active drug to the bloodstream at concentrations sufficient for safety and toxicology studies, as well as achieving single-dose cures.Keywords
This publication has 12 references indexed in Scilit:
- Quinolone-3-Diarylethers: A New Class of Antimalarial DrugScience Translational Medicine, 2013
- Strategies to Address Low Drug Solubility in Discovery and DevelopmentPharmacological Reviews, 2013
- The global pipeline of new medicines for the control and elimination of malariaMalaria Journal, 2012
- The Threat of Artemisinin-Resistant MalariaNew England Journal of Medicine, 2011
- Optimization of endochin-like quinolones for antimalarial activityExperimental Parasitology, 2011
- Hemozoin-free Plasmodium falciparum mitochondria for physiological and drug susceptibility studiesMolecular and Biochemical Parasitology, 2010
- Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparumNature, 2007
- Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug ScreeningAntimicrobial Agents and Chemotherapy, 2004
- Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.The American Journal of Tropical Medicine and Hygiene, 1999
- Human Malaria Parasites in Continuous CultureScience, 1976